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Controlling healthcare budgets is a major priority for all
healthcare systems. In the UK, recommendations for the
role of speciﬁc treatments and disease management
guidelines are produced by organisations such as the
National Institute of Clinical Excellence (NICE). These
recommendations are usually based on cost-effectiveness
(utility) analysis that compares therapies based on a
combination of outcomes. These include: clinical out-
comes (resolution of infection, observed mortality,
projected mortality based on age and disease of patients
alive), economic outcomes (such as overall treatment
costs, including drug acquisition costs, costs due to
adverse events, length of stay (LOS) and treatment swit-
ches) and humanistic outcomes (quality of life or utility
scores). In practice, little if any direct cost-effectiveness
analysis exists to support such decisions.
Our paper focuses on an economic evaluation of anti-
fungal drugs. The economic burden of fungal infections
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Objective: To evaluate the cost-effectiveness of caspofungin vs. liposomal amphotericin B in the treatment
of suspected fungal infections in the UK. Methods: The cost-effectiveness of caspofungin vs. liposomal
amphotericin B was evaluated using a decision-tree model. The decision tree was populated using both
data and clinical deﬁnitions from published clinical studies. Model outcomes included success in terms of
resolution of fever, baseline infection, absence of breakthrough infection, survival and quality adjusted life
years (QALYs) saved. Discontinuation due to nephrotoxicity or other adverse events were included in the
model. Efﬁcacy and safety data were based on additional analyses of a randomised, double blind, multina-
tional trial of caspofungin compared with liposomal amphotericin B. Information on life expectancy,
quality of life, medical resource consumption and costs were obtained from peer-reviewed published
data. Results: The caspofungin mean total treatment cost was £9762 (95% uncertainty interval 6955–
12 577), which was £2033 ()2489; 6779) less than liposomal amphotericin B. Treatment with caspofungin
resulted in 0.40 ()0.12; 0.94) additional QALYs saved in comparison with liposomal amphotericin B. Prob-
abilistic sensitivity analysis found a 95% probability of the incremental cost per QALY saved being within
the generally accepted threshold for cost-effectiveness (£30 000). Additional analyses with varying dose of
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the increased cost of treating systemic fungal infections.
The ever more aggressive and immunosuppressive treat-
ment regimens employed in haematology–oncology result
in longer periods of neutropenia, which in turn have dri-
ven the need for more effective agents against opportun-
istic infections. Much of this is contributed to infections
by Aspergillus spp. Accordingly, new agents effective
against such moulds, such as voriconazole, posaconazole
and echinocandins, are now of considerable interest to
clinicians wishing to eradicate tumour whilst protecting
against, or treating, invasive fungal infections, which
continue to rise inexorably (2–4).
In the UK, accepted standard practice for neutrop-
enic patients with persistent fever includes antifungal
therapy with either conventional amB or liposomal
amphotericin B (L-Amb) (5, 6). An economic analysis
in the USA demonstrated average treatment costs of
about $50 000 with L-Amb and $43 000 with conven-
tional amB (7). These economic analyses are usually
based on head-to-head clinical trials of antifungal
drugs (8, 9). L-Amb was found to be as effective as
conventional amB, but associated with less nehpro-
toxicity, less infusion-related events and less breakthrough
infections (9). Consequently, L-Amb is the preferred
amphotericin formulation in the majority of centres in
the UK.
Caspofungin has been recently licensed in the UK for
empirical therapy for presumed fungal infections (such as
Candida or Aspergillus) in febrile, neutropenic adult
patients. This licence was based upon a randomised,
double blind, multinational study which used L-Amb as
a comparator and demonstrated comparable efﬁcacy as
well as signiﬁcantly less nephrotoxicity (2.6% vs. 11.5%),
deﬁned as a doubling of the serum creatinine level or, if
the creatinine level was elevated at enrolment, an
increase of at least 1 mg per decilitre and other drug-
related events (5% vs. 8%) for the caspofungin treated
arm (8). Voriconazole neither included as a comparator
in this analysis given there is no head-to-head data com-
paring voriconazole with caspofungin, nor indicated in
empirical therapy.
Randomised controlled trials (RCT) are normally not
designed to address questions of economic relevance
unlike health economic-based models. Economic models
integrate the efﬁcacy and safety data obtained from pub-
lished clinical trials, and medical resource consumption
and quality of life (utility) information obtained from the
published literature, expert opinion and database analy-
sis. They additionally make explicit the uncertainties gen-
erated by such a combination of information.
Accordingly, we evaluated the cost-effectiveness of ca-
spofungin and L-Amb for the treatment of suspected
fungal infections in the UK.
Both L-Amb and caspofungin are relatively expensive
agents compared with older antifungals. Additionally, a
recent review by Jorgensen et al. (2006) concluded that
L-Amb is the preferred therapy in suspected fungal infec-
tions (6, 10). We therefore, conducted this study to deter-
mine whether one would be superior to the other in
terms of value for money.
Methods
Model structure
A decision-analytic model (Fig. 1) was developed to
estimate the cost-effectiveness of caspofungin (70 mg
on day one and 50 mg once daily thereafter) vs. L-
Amb (3 mg/kg per day for an average patient weighing
77 kg (based on data for UK patients).
Patients were differentiated according to the presence
(branches P1–P6) or absence of baseline infection (bran-
ches P7–P12). A baseline infection was deﬁned as the
presence of a proven or probable infection on the ﬁrst or
second day of the antifungal treatment (11). Patients
dying prior to 7 d on initial therapy were collapsed into
two branches (P6 and P12), irrespective of premature dis-
continuation of therapy or clinical failure. This was con-
ducted to reduce model complexity and since cause of
death could not be ascertained. However, nephrotoxicity
being a cost driver was estimated within patients that
died. Therefore, our costing process took into considera-
tion the incidence of nehprotoxicity amongst patients
that died on initial therapy (P6 and P12). A patient that
survived initial therapy (branches P1–P5 and P7–P11)
could either continue their initial therapy (P1–P3 and
P7–P9) or discontinue due to drug-related toxicity.
Nephrotoxicity (P4 and P10) being a signiﬁcant cost-
driver was differentiated from other drug-related adverse
events (P5 and P11).
A patient categorised as successful in branch P1 was
deﬁned as having complete resolution of baseline fun-
gal infection, including resolution of their fever during
the neutropenic period, no premature discontinuation
of therapy due to drug-related toxicity, and survival
for 7 d after completion of therapy. A patient catego-
rised as successful in group P7 (those without a base-
line infection) had resolution of fever during the
neutropenic period and no breakthrough fungal infec-
tion (deﬁned as absence of infection from day 3
onward) during therapy or within 7 d after the comple-
tion of therapy, no premature discontinuation of ther-
apy due to drug-related toxicity, and survival for 7 d
after completion of therapy. These deﬁnitions of suc-
cess are in accordance with the ﬁve-component end
point used in clinical trials on empirical antifungal
treatments (6, 8, 9, 12, 13).
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not discontinue due to lack of efﬁcacy, as most of these
patients have been accounted for in other branches rela-
ted to adverse clinical outcomes (P3, P6, P9, P12). An
additional analysis of the trial by Walsh et al. (2004)
supports this assumption (8). If a patient discontinued
initial therapy due to toxicity, a switch to a second line
antifungal drug took place (from caspofungin to L-Amb
or vice versa). Mortality and costs of these second line
antifungal drugs were also included in the model.
The following data were estimated to use within our
model:
(1) Probability that the patient has a successful out-
come, or dies on initial treatment. The conditional
probabilities of efﬁcacy, survival and discontinuation of
initial therapy (Table 1) were based on additional ana-
lyses of the RCT which assessed the efﬁcacy and safety
of caspofungin compared with L-Amb in empirical
therapy (8).
(2) Life years lost: the expected life years lost per treat-
ment arm were calculated by multiplying the probability
of death on ﬁrst line treatment (P6/P12) and the mortal-
ity observed on second line treatment (P4–P5 and P10–
P11) with the life expectancy based on the underlying
condition of patients enrolled in the study.
The estimate for life years lost was based on the life
expectancy of the underlying diagnoses. In the study by
Walsh et al. (2004), 74% of the patients suffered from
acute leukaemia, 11% from non-Hodgkin’s lymphoma
and 15% from other cancers. We used 1- and 5-yr UK
survival data from 1998–2001 (National Statistics, Sur-
vival data England 1998–2001) to calculate life expect-
ancy for each of these conditions (14). Survival
probability for a patient with acute leukaemia was
deﬁned in the model according to ﬁgures reported
within the acute myelogenous leukaemia (AML) trials
of the Medical Research Council. Overall, this resulted
in an average discounted life expectancy of 12.9 yr. For
second line treatment, the probability of dying was
assumed to be 24% (15–33%) based on the study by
Maertens et al. (15) who evaluated patients with fungal
infections who were intolerant or refractory to their ﬁrst
line antifungal agent.
(3) Quality adjusted life years (QALYs) lost: this was
determined by multiplying life years lost in each treat-
ment arm by the utility (or quality of life score) based on
the underlying condition. QALY estimates were discoun-
ted at 3.5% per year according to UK requirements.
Each life year lost was valued with a weighted quality
of life multiplier of 0.72 (0.50–0.94) in order to calculate
the QALYs lost upon death. This utility value for the
deﬁned underlying conditions was based on the catalogue
of preference scores 1997–2000 from the CEA Registry
from the Harvard School of Public Health (http://
www.hsph.harvard.edu). QALYs saved were determined
as the difference between QALYs lost with caspofungin
and L-Amb.
(4) The cost evaluation included: expected antifungal
drug costs (ﬁrst line and second line), other direct costs
(hospitalisation costs + drug costs related to adverse
events) and overall costs. Costs were expressed in 2005
British Pounds (1 pound ¼ 1.80 US dollar).
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Figure 1 Decision-tree model for cost-effectiveness evaluation of caspofungin vs. liposomal amphotericin B in the treatment of suspected.
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To estimate the total cost of the ﬁrst line antifungal
drug use, the average treatment duration by the type of
patient was obtained from Walsh et al. (8). The average
treatment duration of second line antifungal drug was
assumed to be the same as the treatment duration of a
patient that continued initial therapy. The total treat-
ment duration for the patient that discontinued and
switched therapy was calculated as the sum of average
treatment duration of second line drug and the average
treatment duration of the initial drug until discontinu-
ation. Table 2 shows an overview of the treatment dur-
ation we used in the model. The cost per day for
caspofungin was £417 for the ﬁrst day (70 mg) and
£328 per day (50 mg/d) from the second day onwards
(MIMS September 2005). The cost for L-Amb for a 77-
kg patient (3 mg/kg per day) was £483 per day (based
on British National Formulary costs per vial of £96.69
in September 2005).
Toxicity-related cost
Adverse events included in the model were chills, nau-
sea, vomiting, dyspnoea and nephrotoxicity (8). Cost
for chills (£1.1; 0.3–1.9 per event), nausea and vomiting
(£63.9; 50.5–75.3), dyspnoea and ﬂushing (£2.0; 1.6–2.4)
were based on the drug used for these events (expert
opinion and MIMS September 2005). As the cost of
oxygen for dyspnoea can be considered a small expense,
this cost was assumed to be included in the cost due to
LOS in a general ward.
In Table 3, the probabilities of nephrotoxicity by type
of patient in the model are reported. For the patient that
switched to a second line drug in the model (P4–P5 and
P10–P11) the risk of nephrotoxicity for the second line
drug was based on the average probability of nephrotox-
icity seen in the ﬁrst line treatments. Costs for nephrotox-
icity were captured as additional length of hospital stay.
LOS-related cost
A patient is usually not immediately discharged after stop-
ping antifungal therapy. In the UK, we estimated that
patients without serious side effects from the antifungal
treatment stay on average two extra days in hospital.
However, patients experiencing nephrotoxicity stay longer
(estimated as 1.5 times average treatment duration). The
average stay in the Intensive Care Unit (ICU) was sepa-
rately estimated and subtracted from the overall LOS in
the hospital in order to calculate the LOS in the hospital.
Table 2 shows an overview of the LOS used in the hospital
in the model for different types of patients. The average
LOS on the ICU of patients with nephrotoxicity and a
baseline infection was estimated at 0.7 d, in absence of a
baseline infection 0.5 d. The average LOS on the ICU of a
patient without nephrotoxicity and a baseline infection
was estimated at 0.3 d, and in absence of a baseline infec-
tion 0.1 d. We deﬁned per diem cost for stay in general
ward as £316 (NHS reference cost 2004) and the per diem
cost for stay in the intensive care unit as £1238 (NHS refer-
ence cost) (16). The unit cost estimates included average
drug costs and average procedure costs (e.g. lab costs).
Analysis
The source data are characterised by uncertainty. To
incorporate uncertainty in the evaluation, a probabilistic
sensitivity analysis (PSA) was performed to quantify the
uncertainty in model outcomes. A random value was
repeatedly sampled from distributions reﬂecting the uncer-
tainty level of the input source data, plugged into the
model, and then the outcome of the model was calculated.
Each outcome was presented with a point estimate along
with uncertainty reﬂected by the 2.5th and 97.5th percent-
Table 1 Conditional probabilities of discontinuation and efﬁcacy of
ﬁrst line treatment as used in model
Caspofungin L-Amb
Baseline infection 0.05 (0.03–0.07) 0.05 (0.03–0.07)
Survival* 0.93 (0.85–1.00) 0.66 (0.37–0.74)
Continuation of initial
antifungal drug*
0.96 (0.94–0.97) 0.91 (0.89–0.94)
Resolution of baseline infection* 0.56 (0.37–0.75) 0.36 (0.11–0.61)
Discontinuation due to toxicity * 0.04 (0.03–0.06) 0.09 (0.06–0.11)
Success (P1)* 0.29 (0.05–0.52) 0.40 (0.00–0.80)
Resolution of baseline infection,
no resolution of fever (P2)*
0.71 (0.48–0.95) 0.60 (0.20–1.00)
No resolution of baseline
infection (P3)*
0.44 (0.25–0.63) 0.64 (0.39–0.89)
Discontinuation due to
nephrotoxicity (P4)*
0.05 (0.00–0.09) 0.22 (0.09–0.35)
Discontinuation due to
other adverse events (P5)*
0.95 (0.91–1.00) 0.78 (0.65–0.91)
Death (P6)* 0.07 (0.00–0.15) 0.44 (0.26–0.63)
No baseline infection 0.95 (0.93–0.97) 0.95 (0.93–0.97)
Survival* 0.93 (0.90–0.95) 0.91 (0.89–0.93)
Continuation of initial
antifungal drug*
0.96 (0.94–0.97) 0.91 (0.89–0.94)
Discontinuation due to toxicity 0.04 (0.03–0.06) 0.09 (0.06–0.11)
Success (P7)* 0.41 (0.37–0.46) 0.42 (0.38–0.47)
No resolution of fever (P8)* 0.55 (0.50–0.59) 0.54 (0.50–0.59)
Breakthrough infection (P9)* 0.04 (0.02–0.06) 0.03 (0.02–0.05)
Discontinuation due to
nephrotoxicity (P10)*
0.05 (0.00–0.09) 0.22 (0.09–0.35)
Discontinuation due to
other adverse events (P11)*
0.95 (0.91–1.00) 0.78 (0.65–0.91)
Death (P12)* 0.07 (0.05–0.10) 0.09 (0.07–0.11)
* Conditional probabilities (probability given the knowledge that
the event in the previous branch of the tree has occurred) with
uncertainty ranges used for sensitivity analysis.
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(Fig. 2) were created to estimate the probability that
caspofungin would be cost-effective in comparison with
L-Amb for different willingness-to-pay (WTP) ratios,
deﬁned as the assumed maximum amount a decision-
maker would be willing to pay for an additional unit of
beneﬁt (QALY).
Results
Patients treated with caspofungin or L-Amb for a sus-
pected fungal infection had comparable chances of
having a successful outcome (see Table 4). The caspo-
fungin-treated patient group had a lower overall
mortality when compared with the group treated with
L-Amb. When mortality on second line treatment was
also incorporated and expressed as the number of life
years lost relative to the life expectancy of the underly-
ing condition, treatment with caspofungin was predic-
ted to save 0.55 additional life years (95% uncertainty
interval 0.10–0.97) per patient treated compared with
L-Amb. Adjusting for quality of life, caspofungin was
expected to save 0.40 QALYs ()0.13–0.97).
The average total direct costs with caspofungin was
£9763 (6955–12 577; 95% CI) compared with £11 795
(8902–14 724; 95% CI) for L-Amb. This difference was
primarily caused by higher antifungal drug cost observed
for the L-Amb-treated patient.
In Fig. 2, the probability that caspofungin is cost-
effective in comparison with L-Amb is presented for dif-
ferent values of WTP ratios. Such probability reﬂects the
likelihood of cost-effectiveness of caspofungin compared
with L-Amb given the uncertainty of the data inputs.
When the decision-maker is willing to pay for a QALY
saved, we found the probability that caspofungin to be
Table 2 Treatment duration and length of stay in the hospital due to treatment of suspected fungal infection by type of patient
Duration of
initial treatment (days)
Duration of second
line treatment (days)
Length of hospital stay (days)
With nephrotoxicity Without nephrotoxicity
Patient with baseline infection
Patient continued initial therapy
and was successfully treated (P1)
22.0 (13.5–30.5) – 33.0 (16.2–49.8) 24.0 (15.5–32.5)
Patient continued initial therapy, with resolution
of baseline infection but no resolution of fever (P2)
22.5 (15.3–29.7) – 33.8 (18.3–49.2) 24.5 (17.3–31.7)
Patient continued initial therapy, without
resolution of baseline infection (P3)
16.5 (8.2–24.8) – 24.8 (9.9–39.6) 18.5 (10.2–26.8)
Patient discontinued initial therapy
due to nephrotoxicity (P4)
13.6 (1.0–26.3) 19.3 (11.4–27.3) 49.5 (14.8–84.1) –
Patient discontinued initial therapy
due to other adverse events (P5)
13.6 (1.0–26.2) 19.3 (11.4–27.3) 49.4 (14.8–84.0) 34.9 (14.4–55.5)
Patient died during initial therapy (P6) 8.9 (6.8–11.0) – 13.4 (7.9–18.5) 10.9 (8.8–13.0)
Patient without baseline infection
Patient continued initial therapy and
was successfully treated (P7)
15.7 (14.8–16.6) – 23.6 (17.7–29.4) 17.7 (16.8–18.6)
Patient continued initial therapy,
without resolution of fever (P8)
10.7 (9.9–11.5) – 16.1 (11.9–20.2) 12.7 (11.9–13.5)
Patient continued initial therapy, with
a breakthrough infection (P9)
19.9 (13.0–26.8) – 29.9 (15.6–44.1) 21.9 (15.0–28.8)
Patient discontinued initial therapy
due to nephrotoxicity (P10)
12.2 (5.5–18.9) 13.1 (12.1–14.2) 38.0 (21.1–54.9) –
Patient discontinued initial therapy due
to other adverse events (P11)
5.7 (4.2–7.2) 13.1 (12.1–14.2) 28.2 (19.5–37.0) 20.8 (18.2–23.4)
Patient died during initial therapy (P12) 11.2 (8.9–13.5) – 16.8 (10.6–23.0) 13.2 (10.9–15.5)
Table 3 Probability of nephrotoxicity on ﬁrst line treatment by type of
patient as used in model
Caspofungin L-Amb
Type of patient:
Success (P1, P7) 0.01 (0.00–0.02)
1 0.10 (0.06–0.15)
No resolution of fever (P2, P8) 0.02 (0.00–0.04) 0.07 (0.04–0.10)
No resolution of baseline
infection/breakthrough
infection (P3, P9)
0.07 (0.00–0.14) 0.33 (0.09–0.57)
Discontinuation due to
nephrotoxicity (P4, P10)
First line treatment 1.00 (1.00–1.00) 1.0 (1.00–1.00)
Second line treatment 0.12 (0.09–0.14) 0.03 (0.01–0.04)
Discontinuation due to
other adverse events (P5, P11)
First line treatment 0.00 (0.00–0.00) 0.03 (0.00–0.06)
Second line treatment 0.12 (0.09–0.14) 0.03 (0.01–0.04)
Death (P6) 0.12 (0.02–0.22) 0.21 (0.10–0.31)
1 Uncertainty interval used for sensitivity analysis.
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ded 78%. Given the generally accepted maximum WTP
threshold of £20 000 or £30 000 per QALY saved, there
is a 95% probability that caspofungin is cost-effective.
When L-Amb dosages of 1 mg/kg were used instead of
3 mg/kg, the cost difference between caspofungin and
L-Amb was +£1453 ()3179 – +6093), favouring L-Amb.
The resulting cost per QALY saved with caspofungin
relative to L-Amb is expected to be £3665. Although it is
expected there are no cost-savings with caspofungin
relative to 1 mg/kg L-Amb, these incremental cost per
QALY saved are still below generally accepted WTP
threshold of £20 000 per QALY saved. Given the uncer-
tainty in the cost differences and QALYs saved we found
an 85% probability that caspofungin is cost-effective
when compared with L-Amb for this threshold. £20 000
per QALY saved. When L-Amb dosage of 5 mg/kg were
incorporated into the calculations instead of 3 mg/kg,
the savings yielded with caspofungin was £5519 ()10 076
to )1023), resulting in >99% probability of cost-effectiveness
(based on British National Formulary drug prices in Sep-
tember 2005).
Discussion
Cost-effectiveness analysis integrates clinical outcomes
with information relation to both costs and quality of
life. It aims to provide information on the value of a
new intervention compared with the accepted or stand-
ard intervention. Cost-effectiveness does not necessarily
mean cost-saving; the total cost of a new treatment can
be higher, but is still considered good value for money if
it signiﬁcantly enhances quality and duration of life (i.e.
results in a gain in QALYs) over and above the current
best standard.
The economic evaluation described in this paper
applies to treatment of suspected fungal infections in
neutropenic patients in the UK. Our model demonstra-
ted caspofungin to be economically superior to L-Amb
for both QALY gains and cost-savings. The analysis
demonstrated cost-effectiveness of caspofungin when
compared with 1 mg/kg L-Amb and 3 mg/kg L-Amb
(the dose recommended in the L-Amb summary of
product characteristics); both well below the threshold
of £30 000 per QALY deemed acceptable by the
NICE. It must be noted that though we varied the
cost estimates based on different drug doses of
L-Amb, the clinical outcomes were still based on
standard doses used within the Walsh study.
Moreover, the results of our economic analysis is
restricted to the average weight of patients eligible for
empiric therapy (77 kg). Patients with a weight over
80 kg may use higher doses of caspofungin, increasing
overall caspofungin drug costs and changing the results
vs. L-Amb from cost-saving to cost-effective (additional
incremental cost and additional incremental clinical
beneﬁt). However, it is must be noted that some of
empiric therapy patients are well into several courses of
chemotherapy and have lost considerable weight. Addi-
tionally, those prone to serious fungal infection are
often cachectic.
Furthermore, the deﬁnition of success in this analysis
may be underestimated as it is well known that patients
adequately treated for their fungus often remain fever-
ish during neutropenia for a variety of other reasons
(4). Interestingly, a recent analysis using data from the
Walsh study (8) with alternate deﬁnitions of success
(eliminating fever resolution as a component of the
endpoint) showed caspofungin to be clinically superior
to L-Amb (17). Eliminating fever resolution in the cur-
rent economic model, thereby combining branches P1
and P2 and branches P7 and P8, showed that caspo-
fungin was more efﬁcacious (84%; 80–87% probability
Table 4 Outcomes and costs estimated from the model per treat-
ment arm
Caspofungin
estimate
(p2.5–p97.5)
1
L-Amb estimate
(p2.5–p97.5)
Probability of success 0.35 (0.33–0.39) 0.34 (0.31–0.37)
Probability of failure 0.57 (0.54–0.60) 0.55 (0.52–0.59)
Mortality during
initial treatment
0.07 (0.05–0.10) 0.11 (0.08–0.13)
Life years lost 1.08 (0.82–1.38) 1.63 (1.27–1.99)
QALYs lost 0.78 (0.47–1.11) 1.17 (0.78–1.62)
Average total
direct cost
£9763 (6955–12 577) £11 795 (8902–14 724)
Average total
antifungal drug cost
£4601 (4396–4816) £6395 (6112–6705)
First line antifungal cost £4344 (4139–4571) £6067 (5767–6384)
Average other direct cost £5161 (2365–7903) £5400 (2445–8269)
1 Uncertainty range (2.5th percentile and 97.5th percentile of simula-
ted uncertainty distribution).
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Figure 2 Acceptability curve representing the probability that caspo-
fungin is cost-effective in comparison to L-Amb for different values of
willingness-to-pay for a quality adjusted life year saved.
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success), and therefore, dominant over L-Amb because
of lower treatment costs and superior efﬁcacy.
We made several assumptions and simpliﬁcations when
developing our economic model. First, the decision tree
was not designed to support clinical decision-making,
but rather to differentiate between type of patients with
varying degrees of resource consumption, mortality and
success. For example, the ﬁrst branch differentiated
patients with a baseline infection from those without; in
standard practice the presence of baseline infection is
assumed rather than proven at treatment initiation. Sec-
ondly, the implication of assigning life years lost to a
patient who has died, implies that no difference in life
expectancy is assumed between a patient who is success-
fully treated and one whose baseline infection is not suc-
cessfully resolved or experiences a breakthrough
infection. Thirdly, the quality of life during the neutrop-
enic period when treated for the suspected fungal infec-
tion was not taken into consideration in the QALY
calculations due to lack of information available in the
literature. We considered this to be of little relevance as
the average number of life years after the neutropenic
period is much larger than the weeks in a neutropenic
state. QALY estimates in this patient group are therefore
almost completely driven by the quality of life after the
relatively short neutropenic period.
Our model was also simpliﬁed by assuming that a
patient discontinuing ﬁrst line therapy went on to have
a full course of second line therapy. We also assumed
that patients discontinuing caspofungin switched to L-
Amb and vice versa. Conversely, in the Walsh study,
these patients were switched to a diverse mix of differ-
ent antifungal drugs used either alone or as part of
combination therapy. However, as the probability of
discontinuation (of initial therapy) was <10%, it is
unlikely that this assumption will have signiﬁcantly
biased the cost estimates. Additionally, our results are
not applicable to patients who were excluded from the
Walsh study, such as solid-organ transplant patients
and those requiring rifampin, cyclosporine, or concomi-
tant systemic antifungal therapy.
While the RCT by Walsh et al. (8) (the basis for this
analysis) provides a high quality of evidence for the efﬁc-
acy and safety of caspofungin compared with L-Amb,
the actual estimates are characterised by uncertainty (as
represented by 95% CI). Utility and resource use data
used in the evaluation originating from both peer-
reviewed publications and expert opinion confers addi-
tional uncertainty. Model-based economic evaluations
only provide value if the impact of these uncertainties is
accepted and investigated.
The PSA led to a distribution of model outcomes.
More than three quarters (78%) of the analyses varying
input values resulted in cost-savings with caspofungin
relative to L-Amb. Ninety-ﬁve per cent (95%) of the
analyses provided a cost per QALY falling below a will-
ingness to pay of £30 000 (see Fig. 2). We conclude that
when accounting for every aspect of uncertainty of the
input data, caspofungin remains cost-effective compared
with L-Amb (95% probability); we furthermore placed a
78% probability on this drug resulting in a net saving.
From a cost-effectiveness perspective, the disadvanta-
ges of L-Amb over caspofungin are the higher treatment
costs due to increased likelihood of adverse events inclu-
ding the higher probability of nephrotoxicity and related
discontinuation. Nephrotoxicity results in higher medical
costs due to an increased LOS. Discontinuation of initial
treatment and switch to second line therapy, subsequent
to an adverse event, may result in increased overall dur-
ation of the antifungal therapy, additional length of hos-
pital stay, and a further increase in cost. Furthermore,
nephrotoxicity may even delay the next cycle of chemo-
therapy, with possible consequences on disease progres-
sion and overall survival.
Our study suggests that caspofungin remains not only
a cost-effective therapy for the treatment of suspected
fungal infections in the febrile neutropenic patient when
compared with L-Amb, but may also generate savings in
treatment costs and gains in QALYs. Given limited
healthcare budgets, our ﬁndings suggest the possibility
that such savings might contribute towards treating more
patients with better outcomes. Finally, these ﬁndings
were based on drug prices which were published in Sep-
tember 2005 and the model furthermore assumed
patients to all weight 77 kg. Local drug pricing variation
and patient casemix, may all signiﬁcantly impact on our
conclusions.
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